Improved Graft Function and Decreased Post-transplantation Urinary Tract Infection after Azithromycin Dosing to...

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• End-stage Renal Disease (ESRD) is increasing, necessitating improved kidney transplantation outcomes.
• Kidney transplantation is the optimal treatment for ESRD, but graft survival requires enhancement.
• Macrolide antibiotics, like azithromycin, possess immunomodulatory and anti-inflammatory properties with tissue-specific accumulation.

Purpose of the Study:

• To evaluate the efficacy of a single donor dose of azithromycin in improving kidney transplant outcomes.
• To assess the impact of perioperative azithromycin on graft function, rejection rates, and infections.

Main Methods:

• A double-blinded, randomized clinical trial involving 62 kidney donors.
• Donors received either a single 1-gram dose of azithromycin or a placebo one day before nephrectomy.
• Outcomes including graft function, rejection, infections, and donor/recipient complications were monitored up to 90 days post-transplant.

Main Results:

• Azithromycin administration was associated with a reduced early rejection rate post-kidney transplantation.
• Lower levels of inflammatory mediators were observed in the azithromycin group.
• Fewer urinary tract infections occurred in recipients whose donors received azithromycin (p < 0.05).

Conclusions:

• Perioperative donor azithromycin is a safe and effective strategy to mitigate adverse outcomes in kidney transplantation.
• This intervention enhances kidney graft function and reduces the incidence of post-transplant complications.
• Azithromycin offers an accessible and cost-effective method for improving kidney transplant success rates.